Bioactive Polysaccharides Based Graphene Oxide Nanoparticle as a Promising Carrier for Anticancer Drug Delivery

Nowadays, the concept of drug transmission is a prominent issue in the world of drug delivery research. We investigated the development of a hybrid platform based on graphene oxide/chitosan and xyloglucan (GO-CH-Xn) for the loading and release of doxorubicin (DOX)., where chitosan (CS) natural polymer functionalizes graphene oxide and is then grafted by xyloglucan (Xn) natural hydrophilic polysaccharide to form a reliable nanocarrier system for the delivery of DOX. UV-Vis spectroscopy, Fourier transform infrared spectroscopy, X-ray diffraction, Raman spectroscopy, transmission electron microscopy, and scanning electron microscopy analysis were used to confirm the fundamental physicochemical properties. The DOX loading capacity and efficiency were 81.8% and 73.5%. The graphene oxide-chitosan-xyloglucan- doxorubicin (GO-CS-Xn-DOX) drug delivery system showed a pH-regulated release as observed by UV analysis. Biocompatibility was evaluated via in vitro hemolysis assay, indicates negligible toxicity, and the anticancer activity of the developed nanocarrier system was studied by 3-(4, 5-dimethylthiazol-2-Y)-2,5-diphenyltetrazolium bromide (MTT) against human (U 87) glioblastoma cancer cell lines. The in vitro studies demonstrate the major advantages of the developed approach by demonstrating its capability as a promising nanocarrier for biomedical applications.